ATLANTA — A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in pediatric and adult patients with advanced HER2-positive sarcoma, according to results...
A brain-cancer vaccine more than 20 years in the making suspends cancer growth in patients enrolled in early-stage trial. Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a...
-First patient enrolled in COMPARE trial evaluating efficacy and safety of SEL-212 v. KRYSTEXXA® in patients with chronic refractory gout -Strengthened management and clinical teams with the appointments of Elona Kogan, J.D. as General Counsel & Corporate...
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Novartis will present a poster with data from an ongoing clinical trial evaluating the...
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. A phase I clinical trial that set out to assess the safety of a new combination...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies (MISSION AD) on the investigational oral BACE (beta amyloid...
Email
Text